GLP-1

FDA Approves First Interchangeable Biosimilar GLP-1 Weight Loss and Diabetes Injection

Food and Drug Administration Commissioner Robert Califf approves the first generic interchangeable biosimilar GLP-1 receptor agonist, slashing monthly retail prescription costs from $1,000 down to under $150.